Access to Investigational Medicines

Expanded Access Policy

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.

We are currently in the clinical testing stage of development. The completion of such controlled studies is required to generate the evidence regarding clinical safety and efficacy that is necessary to secure government approval and make new medicines available to a wider population of patients.

We understand that there may be interest in accessing our investigational medications prior to approval. At this time, our efforts are focused on the careful design and successful completion of clinical trials in collaboration with patients, families, advocacy groups, physicians, scientists and government agencies. We believe that this is the best way to generate information that may be critical to positively impact a much larger population in the future. Therefore, we encourage all eligible participants to consider enrolling in our ongoing or planned clinical trials.

For more information on clinical trials of our investigational medicines, see https://www.clinicaltrials.gov/search?spons=Longboard%20Pharmaceuticals.

Under limited and unique circumstances, and/or for patients who do not qualify to participate in a clinical trial, a request for expanded access may be considered if submitted on their behalf via a licensed physician who believes the potential benefits outweigh the risks to the patient from the investigational medication. Some of the other criteria we may consider include the available information about safety, tolerability and effectiveness, the potential to interfere with the conduct of clinical trials or regulatory approval of our investigational medicines, whether there is a sufficient supply of investigational product, and the availability of alternative treatments. Physicians may submit requests for expanded access via [email protected], and we will respond within five business days of receipt of any such request.

If you have any questions, please contact us at [email protected].

Last updated: August 1, 2024